Incidence of lymphoproliferative disorders after renal transplantation is down, but the poor prognosis remains. Multicenter 32-year cohort study

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Franco, Antonio
  • dc.contributor.author Hernández, Domingo
  • dc.contributor.author Más-Serrano, Patricio
  • dc.contributor.author Zarraga, Sofia
  • dc.contributor.author Sanchez, Ana
  • dc.contributor.author Crespo Barrio, Marta
  • dc.contributor.author Mazuecos, Auxiliadora
  • dc.contributor.author Diaz-Corte, Carmen
  • dc.contributor.author Rodriguez-Benot, Alberto
  • dc.contributor.author Jimenez, Carlos
  • dc.contributor.author Gonzalez, Yussel
  • dc.date.accessioned 2023-05-16T06:15:37Z
  • dc.date.available 2023-05-16T06:15:37Z
  • dc.date.issued 2022
  • dc.description.abstract Background: Post-transplant lymphoproliferative disorders represent rare but serious complications of kidney transplantation. Methods: We assessed incidence, risk factors, and outcomes in 21,546 patients receiving grafts between 1990 and 2009. Data were compared by decade of transplant (1990-1999 vs 2000-2009). Patients were followed for at least 12 years over a 32-year study period. Results: In total, 331 patients (1.5%) developed PTLD: 189 of 9740 transplanted in the first decade, and 142 of 11,806 in the second. Incidence decreased significantly (19.40 vs12.02 cases/1000 patients; P < .001). Mean age at diagnosis was 50.2 years (standard deviation 14.7), and the median time from transplant to PTLD diagnosis was 48 months (interquartile range, 14.7-77.5), with no difference between cohorts. The origin of PTLD was mostly (86%) B-cell proliferation. No classical risk factors were reported in 31.7% of affected patients. Compared with 2000 to 2009, in 1990 to 1999 there was a higher frequency of induction therapy (P = .023) and detection of the Epstein-Barr virus in lymphoproliferative tissue (71.3% vs 52.7% P = .019). After diagnosis, 1- and 5-year patient survival was 51% and 38%. Graft survival was 48% and 33%. Survival was stable throughout the study period. Conclusion: Post-transplant lymphoproliferative disorders have a low and decreasing incidence, but the poor prognosis has not changed.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Franco A, Hernández D, Más-Serrano P, Zarraga S, Sanchez A, Crespo M, Mazuecos A, Diaz-Corte C, Rodriguez-Benot A, Jimenez C, Gonzalez Y. Incidence of lymphoproliferative disorders after renal transplantation is down, but the poor prognosis remains. Multicenter 32-year cohort study. Transplant Proc. 2022 Nov;54(9):2462-6. DOI: 10.1016/j.transproceed.2022.10.017
  • dc.identifier.doi http://dx.doi.org/10.1016/j.transproceed.2022.10.017
  • dc.identifier.issn 0041-1345
  • dc.identifier.uri http://hdl.handle.net/10230/56817
  • dc.language.iso eng
  • dc.publisher Elsevier
  • dc.relation.ispartof Transplant Proc. 2022 Nov;54(9):2462-6
  • dc.rights © 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
  • dc.title Incidence of lymphoproliferative disorders after renal transplantation is down, but the poor prognosis remains. Multicenter 32-year cohort study
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)